SUPPLEMENTARY MATERIAL

Treatment-Emergent Mutations and Resistance in HIV-Infected Children Treated with Fosamprenavir-Containing Antiretroviral Regimens

Lisa L. Ross¹, Mark F. Cotton², Haseena Cassim³, Eugeny Voronin⁴, Naomi Givens⁵, Jorg Sievers⁵, and Katharine Y. Cheng⁵ For the APV29005 & APV20002 Pediatric Study Groups

¹ViiV Healthcare, Research Triangle Park, NC, USA

²Department of Pediatrics and Child Health, Children's Infectious Diseases Clinical Research Unit, Stellenbosch University, Tygerberg, South Africa

³Perinatal HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa

⁴Republic Hospital of Infectious Disease, St. Petersburg, Russian Federation

⁵GlaxoSmithKline, Stockley Park, UK

Viral response profiles for APV29005 FPV-treated VF patients whose virus selected treatment-emergent NRTI or PI mutations or reduced susceptibility at VF




Fig. (1). Viral response profiles for the three FPV-treated patients from the APV29005 Study (all previously ART-naïve) who met VF criteria and whose virus selected treatment-emergent NRTI or PI mutations or developed treatment-emergent reduced drug susceptibility at VF. Drugs with baseline RS are shown in **bold** throughout. All treatment-emergent changes are shown in red with <u>bold underlining</u>. Drug abbreviations are as follows: abacavir (ABC); atazanavir (ATV); didanosine (ddI); emtricitabine (FTC); darunavir (DRV); delavirdine (DLV); efavirenz (EFV); fosamprenavir (FPV); indinavir (IDV); lamivudine (3TC); lopinavir (LPV); nelfinavir (NFV); nevirapine (NFV); ritonavir (RTV); saquinavir (SQV); stavudine (d4T); tenofovir (TDF); tipranavir (TPV); zidovudine (ZDV). FC=Fold change. WT= wild-type virus. RT=reverse transcriptase. PRO=protease.

Viral response profiles for APV29005 FPV/RTV-treated VF patients whose virus selected treatmentemergent NRTI or PI mutations or reduced susceptibility at VF




Fig. (2). Viral response profiles for four FPV/RTV-treated patients from the APV29005Study (all ART-experienced) who met VF criteria and whose virus selected treatment-emergent NRTI or PI mutations or developed treatment-emergent reduced drug susceptibility at VF. One additional viral response profile from an ART and PI-experienced patient who met VF at week 48 but whose virus selected only the treatment-emergent minor viral NNRTI polymorphism mixture K101K/E with no change in drug susceptibility is not shown. Drugs with baseline RS are shown in **bold** throughout. All treatment-emergent changes are shown in red with <u>bold underlining</u>. Drug abbreviations are as follows: abacavir (ABC); atazanavir (ATV); didanosine (ddI); emtricitabine (FTC); darunavir (DRV); delavirdine (DLV); efavirenz (EFV); fosamprenavir (FPV); indinavir (IDV); lamivudine (3TC); lopinavir (LPV); nelfinavir (NFV); nevirapine (NFV); ritonavir (RTV); saquinavir (SQV); stavudine (d4T); tenofovir (TDF); tipranavir (TPV); zidovudine (ZDV). FC=Fold change. WT= wild-type virus. RT=reverse transcriptase. PRO=protease.

Viral response profiles for APV20002 FPV/RTV-treated VF patients whose virus selected treatmentemergent NRTI or PI mutations or reduced susceptibility at VF




Fig. (3). Viral response profiles for the three APV20002 FPV/RTV-treated patients with VF whose virus selected treatment-emergent NRTI or PI mutations or developed treatment-emergent reduced drug susceptibility at VF. Drugs with baseline RS are shown in **bold** throughout. All treatment-emergent changes are shown in red with <u>bold underlining</u>. Drug abbreviations are as follows: abacavir (ABC); atazanavir (ATV); didanosine (ddI); emtricitabine (FTC); darunavir (DRV); delavirdine (DLV); efavirenz (EFV); fosamprenavir (FPV); indinavir (IDV); lamivudine (3TC); lopinavir (LPV); nelfinavir (NFV); nevirapine (NFV); ritonavir (RTV); saquinavir (SQV); stavudine (d4T); tenofovir (TDF); tipranavir (TPV); zidovudine (ZDV). FC=Fold change. WT= wild-type virus. RT=reverse transcriptase. PRO=protease.

Study Week